Notícias

Investing.com -- Citi has downgraded Boston Scientific to Neutral from Buy, citing an uncertain recovery path after a string of setbacks this year.

Boston Scientific (BSX) flagged its inability to meet its near-term financial outlooks amid a "mater

The medical device maker said it is unlikely to meet its full-year sales growth and adjusted earnings targets, and will update investors on Oct. 28

Boston Scientific stock falls as the medical device maker says a recent cyberattack may make it hard to hit quarterly and full-year guidance targets.

On Aug. 26, 2026, a cyberattack halted order processing and shipping at the medical device maker, leaving investors uncertain about the speed of recovery and near-term shipment delays.

Shares of medical-device maker Boston Scientific are down 4.5% Wednesday on concerns that a cyber-attack against the company could hurt near-term revenue. The incident, which Boston Scientific said it detected Tuesday, caused a network outage and disruption to operations, including the ability to process and ship orders, a spokeswoman said. Evercore ISI analysts noted that a similar cyberattack against medical-device maker Stryker in March took about three weeks for the company to recover from.

Boston Scientific recently reported its second-quarter 2026 results, showing sales of US$5,442 million and net income of US$907 million, alongside issuing a recall of its Rapid Refill Continuous Injection System and initiating a multi-year global restructuring plan aimed at cost efficiencies. While the company raised full-year 2026 net sales growth expectations to approximately 5.5%–6.5%, it also outlined a restructuring program costing up to US$800 million and targeting around US$500...

Boston Scientific logged higher second-quarter results and cut its full-year outlook as it begins a new restructuring plan announced earlier this week.

Medical device company Boston Scientific (NYSE:BSX) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 7.5% year on year to $5.44 billion. On the other hand, next quarter’s revenue guidance of $5.27 billion was less impressive, coming in 2.2% below analysts’ estimates. Its non-GAAP profit of $0.86 per share was 3.8% above analysts’ consensus estimates.

Investors weigh softer WATCHMAN and urology demand against a still-active device pipeline and capital deployment moves, today, May 27, 2026.

The Dow Jones Industrial Average was up, while the S&P 500 and Nasdaq Composite were about flat in l